Walker PR Saas P Dietrich PY 1998 Tumors of diverse origin have recently been shown to express CD95 ligand and to induce apoptosis in CD95-expressing targets in vitro; however, in vivo, enhanced tumor growth and rejection have both been observed as a consequence of either immunosuppressive or proinflammatory functions of CD95 ligand. The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment. https://sonar.ch/global/documents/5190 eng info:eu-repo/semantics/altIdentifier/doi/10.1016/s0952-7915(98)80225-2 info:eu-repo/semantics/altIdentifier/pmid/9794830 Current opinion in immunology. - 1998 Animals Fas Ligand Protein Humans Membrane Glycoproteins Neoplasms T-Lymphocytes Tumor expression of Fas ligand (CD95L) and the consequences. http://purl.org/coar/resource_type/c_6501